← All themes Genomics & Gene Editing

Gene Therapy

Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.

131 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Novartis NVS $279B	848	+17	+2%	$21.5B
2	2 Charles River Laboratories CRL $14.4B	262	+4	+2%	$2.6B
3	3 DELISTED SANGAMO THERAPEUTICS INC SGMO	156	+11	+8%	$747M
4	4 Sarepta Therapeutics SRPT $1.78B	128	+14	+12%	$794M
5	5 Precigen PGEN $2.64B	107	+7	+7%	$2.18B
6	6 DELISTED bluebird bio BLUE	104	+21	+25%	$742M
7	ISEE 7 DELISTED IVERIC bio, Inc. Common Stock ISEE	98	+25	+34%	$1.18B
8	8 PTC Therapeutics PTCT $4.98B	84	+19	+29%	$601M
9	9 Ultragenyx Pharmaceutical RARE $1.47B	81	+4	+5%	$816M
10	10 Lineage Cell Therapeutics LCTX $232M	62	+4	+7%	$66.3M
11	11 Fortress Biotech FBIO $63.4M	48	-9	-16%	$15.9M
12	ATHX 12 DELISTED Athersys, Inc. Common Stock ATHX	46	-11	-19%	$21.2M
13	13 DELISTED Carisma Therapeutics CARM	39	+7	+22%	$153M
14	AGTC 14 DELISTED Applied Genetic Technologies Corporation AGTC	38	+37	+3,700%	$74.3M
15	15 Imunon IMNN $5.84M	36	+6	+20%	$10.3M
16	16 Opus Genetics IRD $341M	35	0	0%	$6.57M
17	17 Pluri PLUR $11.7M	28	+6	+27%	$3.25M
18	18 uniQure QURE $1.45B	27	+1	+4%	$46.5M
19	19 Vericel Corp VCEL $2.06B	26	+6	+30%	$2.99M
20	20 Fate Therapeutics FATE $232M	22	+1	+5%	$62.4M
21	21 Neurogene NGNE $444M	19	-4	-17%	$41.1M
22	PTE 22 DELISTED PolarityTE, Inc. Common Stock PTE	16	+16	–	$754K
23	23 DELISTED BioLife Solutions BLFS	14	+14	–	$1.32M
24	24 Eterna Therapeutics ERNA $2.46M	7	+2	+40%	$9.86M
25	25 DELISTED Scorpius Holdings, Inc. SCPX	1	0	0%	$4.91M